Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03688074 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
NCT03688074 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 116 participants.
The verdict
NCT03688074, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
Study Summary
A phase 2, multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of tezepelumab on airway inflammation in adults with inadequately controlled asthma.
Interventions
- OTHER Placebo
- BIOLOGICAL Tezepelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2018-11-02 |
| Est. Completion | 2020-11-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03688074
The ClinicalTrials.gov registry entry for NCT03688074 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03688074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03688074 about?
NCT03688074 is a clinical study titled "Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)". A phase 2, multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of tezepelumab on airway inflammation in adults with inadequately controlled asthma.
What is the current status of trial NCT03688074?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2018-11-02. Estimated completion is 2020-11-16.
What interventions are being tested in trial NCT03688074?
The interventions under investigation include: Placebo (OTHER), Tezepelumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03688074?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.